Presentation Information

[1P-0455 (1AT1-10-03)]PRAME drives BCG resistance in non-muscle-invasive bladder cancer by suppressing the RIG-I–MAVS–IRF3–type I interferon axis

○Miyu Azuma1, Moritoshi Sakamoto1,2, Kazuki Nishimura1,2, Ryoichi Maenosono1,2, Maiko Seki1, Kensuke Hirosuna1,2, Masahiko Ajiro1, Asuka Kawachi1, Junko Mukohyama1,3, Takuya Tsujino1,2, Mitsuaki Ishida4, Kazumasa Komura5, Haruhito Azuma2, Akihide Yoshimi1 (1.Division of Cancer RNA Research, National Cancer Center Research Institute , 2.Department of Urology, Osaka Medical and Pharmaceutical University , 3.Department of Surgery, The Institute of Medical Science, The University of Tokyo, 4.Department of Pathology, Osaka Medical and Pharmaceutical University, 5.Department of Urology, Kawasaki Medical School)

Password required to view

Password required to view or download.
Check your name badge for the password.

Comment

To browse or post comments, you must log in.Log in